Lysophosphatidate Signaling: The Tumor Microenvironment’s New Nemesis

Lysophosphatidate Signaling: The Tumor Microenvironment’s New Nemesis

1 Department of Cancer Biology, University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614, USA *Correspondence: saori.furut...

773KB Sizes 0 Downloads 6 Views

1

Department of Cancer Biology, University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614, USA *Correspondence: [email protected] (S. Furuta). http://dx.doi.org/10.1016/j.trecan.2017.09.003

References 1. Iwakiri, Y. et al. (2006) Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein Snitrosylation and protein trafficking. Proc. Natl. Acad. Sci. U. S. A. 103, 19777–19782

18. Gonzalez, D.R. et al. (2007) Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 104 (51), 20612–20617 19. Yakushev, S. et al. (2012) Cross talk between S-nitrosylation and S-glutathionylation in control of the Na,KATPase regulation in hypoxic heart. Am. J. Physiol. Heart. Circ. Physiol. 303 (11), H1332–H1343 20. Nakamura, T. et al. (2013) Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron 78 (4), 596–614 21. Dalle-Donne, I. et al. (2000) S-NO-actin: S-nitrosylation kinetics and the effect on isolated vascular smooth muscle. J. Muscle. Res. Cell. Motil. 21 (2), 171–181

2. Hess, D.T. and Stamler, J.S. (2012) Regulation by S-nitrosylation of protein post-translational modification. J. Biol. Chem. 287, 4411–4418

22. Erickson, J.R. et al. (2015) S-Nitrosylation Induces Both Autonomous Activation and Inhibition of Calcium/Calmodulin-dependent Protein Kinase II d. J. Biol Chem 290 (42), 25646–25656

3. Simon, D.I. et al. (1996) Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc. Natl. Acad. Sci. U. S. A. 93, 4736–4741

23. Jaffrey, S.R. et al. (2001) Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell. Biol. 3 (2), 193–197

4. Mannick, J.B. et al. (2001) S-nitrosylation of mitochondrial caspases. J. Cell Biol. 154, 11111–11116

24. Marshall, H.E. et al. (2004) S-nitrosylation: Physiological regulation of NF-kB. Proc. Natl. Acad. Sci. U. S. A. 101 (24), 8841–8842

5. Xu, L. et al. (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279, 234–237 6. Schonhoff, C.M. et al. (2006) S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103, 2404–2409 7. Uehara, T. et al. (2006) S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441, 513–517 8. Numajiri, N. et al. (2011) On–off system for PI3-kinase–Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc. Natl. Acad. Sci. U. S. A. 108, 10349–10354 9. Reynaert, N.L. et al. (2004) Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. U. S. A. 101, 8945–8950 10. Nakamura, T. et al. (2010) Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol. Cell. 39, 184–195 11. Straub, A.C. et al. (2011) Compartmentalized connexin 43 S-nitrosylation/denitrosylation regulates heterocellular communication in the vessel wall. Arterioscler. Thromb. Vasc. Biol. 31, 399–407 12. Bakhshi, F.R. et al. (2012) S-nitrosylation of caveolin-1 Cys156 stimulates Src-dependent caveolin-1 Tyr14 phosphorylation required for caveolae-mediated endocytosis in endothelial cells. FASEB J. 26 (Suppl. 1), 1130.10 13. Bakhshi, F. et al. (2010) S-nitrosylation of caveolin-1 Cys156 regulates oligomer stability and caveolae trafficking. FASEB 24 (Suppl. 1), 797.6 14. Godoy, L.C. et al. (2010) Loss of CD40 endogenous S-nitrosylation during inflammatory response in endotoxemic mice and patients with sepsis. Shock 33 (6), 626–633 15. Retamal, M.A. et al. (2006) S-nitrosylation and permeation through connexin 43 hemichannels in astrocytes: induction by oxidant stress and reversal by reducing agents. Pharmaceuticals (Basel) 103 (12), 4475–4480 16. Ravi, K. et al. (2004) S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc. Natl. Acad. Sci. U. S. A. 101 (8), 2619–2624 17. Ho, G.P. et al. (2011) S-nitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95. Neuron 71 (1), 141

748

Trends in Cancer, November 2017, Vol. 3, No. 11

25. Park, H.S. et al. (2000) Nitric oxide negatively regulates cJun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc. Natl. Acad. Sci. U. S. A. 97 (26), 14382–14387 26. Pearce, L.L. et al. (2000) Metallothionein, nitric oxide and zinc homeostasis in vascular endothelial cells. J Nutr 130 (5S Suppl), 1467S–1470S 27. Marshall, H.E. and Stamler, J.S. (2001) Inhibition of NFkappa B by S-nitrosylation. Biochemistry 40 (6), 1688– 1693 28. Hao, G. et al. (2006) SNOSID, a proteomic method for identification of cysteine S-nitrosylation sites in complex protein mixtures. Proc. Natl. Acad. Sci. U. S. A. 103 (4), 1012–1017 29. Sengupta, R. and Holmgren, A. (2012) The role of thioredoxin in the regulation of cellular processes by S-nitrosylation. Biochim. Biophys. Acta 1820 (6), 689–700 30. Sun, J. et al. (2007) Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Cir. Res. 101 (11), 1155–1163 31. Cho, D.H. et al. (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324 (5923), 102–105 32. Fare, s.A. et al. (2011) Proteomics investigation of endogenous S-nitrosylation in Arabidopsis. Biochem. Biophys. Res. Commun. 416 (3–4), 331–336 33. Kornberg, M.D. et al. (2010) GAPDH mediates nitrosylation of nuclear proteins. Nat. Cell. Biol. 12 (11), 1094–1100 34. Wang, P. et al. (2009) Repression of classical nuclear export by S-nitrosylation of CRM1. J. Cell. Sci. 122 (Pt 20), 3772–3779 35. Yu, Z. et al. (2006) Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene. J. Biol. Chem. 281 (14), 9101–9109 36. Kuncewicz, T. et al. (2003) Proteomic analysis of S-nitrosylated proteins in mesangial cells. Mol. Cell. Proteomics 2 (3), 156–163 37. Veron, D. et al. (2014) Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice. J. Am. Soc. Nephrol. 25 (8), 1814–1824 38. Zhang, R. et al. (2016) Hemoglobin S-nitrosylation plays an essential role in cardioprotection. J. Clin. Invest. 126 (12), 4654–4658

Forum

Lysophosphatidate Signaling: The Tumor Microenvironment’s New Nemesis Matthew G.K. Benesch,1,2 Zelei Yang,2 Xiaoyun Tang,2 Guanmin Meng,2 and David N. Brindley2,* Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating chronic inflammation, irrespective of diverse mutations within cancer cells. Overview Cancer research has classically concentrated on cancer cells and their innate characteristics, but this focus is shifting towards the permissibility of host tissues that enable cancer initiation and progression. We focus here on extracellular LPA signaling through its six G protein-coupled receptors as a crucial component of the tumor microenvironment. LPA promotes tumor growth, metastasis, angiogenesis, and immune evasion, and it diminishes the efficacies of radiotherapy and chemotherapy [1]. Most extracellular LPA is produced from plasma lysophosphatidylcholine by the secreted enzyme, autotaxin [2]. LPA signaling is terminated through rapid

degradation of LPA by a family of three lipid phosphate phosphatases (LPPs) (Figure 1A). Knockout of autotaxin is embryonically lethal because LPA signaling is essential for embryonic development. However, postnatal decreases in the expression of autotaxin and changes in expression of the LPPs produce little obvious phenotypic change. Therefore, pharmacological targeting of autotaxin is well tolerated, probably because some LPA can still be produced by phospholipase A type activities.

cancer cells in melanomas, glioblastomas, and thyroid cancers (Figure 1B) [4]. Autotaxin gene copy numbers are amplified in 10–20% of some cancers [6]. The possibility that other neighboring genes in the locus are also amplified and contribute to the malignant phenotype is poorly understood and warrants further investigation. Autotaxin mutations are extremely rare [6]. We recently established a novel alternative model of increased autotaxin production in breast cancer where cancer cells produce little autotaxin. Instead, inflammatory cytokines and chemokines from breast cancer cells induce autotaxin expression in tumorassociated fibroblasts and adjacent adipose tissue, and this increases breast cancer progression (Figure 1B) [2,4]. Significantly, 40% of body autotaxin is produced by adipocytes, and this is increased further by inflammation in obesity linked to insulin resistance. Increased autotaxin from adipocytes could provide a possible link between obesity and its contribution to an estimated 20–40% of breast cancers [4].

A major physiological function of LPA in adults is to facilitate wound healing in response to acute inflammation [2]. LPA suppresses autotaxin gene (ENPP2) expression through PI3K signaling, but parallel signaling by inflammatory cytokines counteracts this effect to increase autotaxin production (Figure 1A) [2]. LPA increases platelet aggregation and the migration of cells that are needed for tissue repair and angiogenesis [2]. LPAmediated lymphocyte extravasation maintains immune homeostasis and stimulates the conversion of monocytes to macrophages [3]. When tissue repair is achieved, inflammation resolves and Upregulation of LPA receptors (LPARs) in autotaxin secretion decreases [2]. multiple cancers is linked to a more invasive phenotype. Elevation of LPAR1 is Maladaptations of LPA Signaling correlated with downregulation of the tumor-suppressor p53 in hepatocellular in Cancers The tissue-remodeling, repair, and immu- carcinomas [7]. LPAR2 is significantly nological effects of LPA become expressed in ovarian and colon cancers maladaptive in chronic inflammatory dis- where it is closely associated with eases including pulmonary fibrosis, increased levels of multiple pro-angiorheumatoid arthritis, atherosclerosis, genic agonists [7]. Tumors commonly inflammatory bowel disease, hepatitis, display decreased LPP1 and LPP3 and cancers (wounds that do not heal) expression, which aggravates the effects [2]. These conditions involve a vicious of increased autotaxin activity and LPAR cycle in which inflammatory cytokines expression by decreasing LPA turnover increase autotaxin secretion and LPA [8]. The LPP1 gene (PLPP1) was also production, which in turn stimulates the recently identified as one of 12 markers expression of cyclooxygenase 2 (COX-2) that predict poor survival for breast canas well as additional inflammatory cyto- cer patients [9]. kines and chemokines (Figure 1B) [4,5]. Chronic inflammatory conditions such as LPA Signaling in Metastasis and inflammatory bowel diseases and hepati- Resistance to Therapy tis predispose to cancer development. The major obstacles to effective cancer Autotaxin can be produced directly by treatment are preventing metastasis and

the loss of efficacy of chemotherapy and radiotherapy [1,6,10]. LPA contributes to metastasis by increasing tumor growth and angiogenesis, as well as by acting as a potent motility factor. LPA is implicated in epithelial-to-mesenchymal (EMT) transitions that facilitate cancer cell spread beyond the primary tumor [6]. The subsequent mesenchymal-to-epithelial (MET) transition facilitates seeding of cancer cells at distant sites. During these transitions, cancer cells must evade the immune system during extravasation and survive at distant sites long enough to establish secondary tumors. LPA facilitates this in part by inhibiting CD8+ T cell activation, and this could suppress adaptive immunity [11]. Furthermore, the LPA reservoir in platelets promotes the survival of circulating cancer cells and subsequent bone metastases [12]. In addition, multiple myeloma (MM) cells stimulate mesenchymal stroma cells (MSCs) at sites of metastases to produce autotaxin [13]. Interestingly, differential LPA signaling through LPAR1 and LPAR3 transduces opposing signals to determine the fate of MSCs. Silencing LPAR3 in MSCs leads to cellular senescence-related phenotypes, transdifferentiation into tumorassociated fibroblasts, and tumor-related angiogenesis in response to stimulation by MM cells. By contrast, MSCs in which LPAR1 signaling was impaired were refractory to cellular senescence and transdifferentiation into tumor-associated fibroblasts, and had reduced MM-promoting abilities [13]. Overall, how LPA signaling in stroma cells promotes metastases provides an active area of investigation. Increased LPA signaling contributes to the loss of therapeutic efficacy of doxorubicin, paclitaxel, tamoxifen, cisplatin, and ionizing radiation [1,5,10,14,15]. This can be explained partly by LPA-induced increases in the expression of the transcription factor, Nrf-2, which promotes the synthesis of antioxidant proteins and multidrug-resistance transporters. This protects cancer cells against

Trends in Cancer, November 2017, Vol. 3, No. 11

749

O

(A)

LPC

O O

n

HO H

O P O O−

Tissue injury

N+

ATX O

LPA n

O

HO H

O O P OH O−

O n

MAG O

HO H

C

OH

Extracellular LPARs

LPPs

PI3K

Intracellular

ATX (B)

LPC

ATX

LPC

ATX

LPA

Cancer cell

C

LPA LPARs

C Adipose ssue/ tumor stroma

LPARs

PI3K MDRTs NF-κB Nrf-2

COX-2 DNA damage

Anoxidants Oxidave damage

Chemotherapy

Radiotherapy

Figure 1. Overview of Autotaxin (ATX)–Lysophosphatidate (LPA)–Lipid Phosphate Phosphatase (LPP) Signaling. (A) Most extracellular LPA is produced by the enzyme ATX from plasma lysophosphatidylcholine (LPC). LPA then signals through its six G protein-coupled receptors (LPARs). LPA is degraded by lipid phosphate phosphatases (LPPs) to form inactive monoacylgylcerol (MAG), terminating the signal. ATX protein production is negatively regulated by LPA through phosphatidylinositol-3-kinase (PI3K) signaling. Cytokines and chemokines, C, produced in response to tissue injury signal through their own receptors to upregulate ATX expression and overcome the inhibition by LPA. When tissue repair is complete, the inflammatory signal is terminated and ATX levels fall. ATX production is maintained in chronic inflammation. (B) ATX is produced directly by cancer cells in melanomas, glioblastomas, and thyroid tumors (blue arrows). ATX in breast cancer is secreted by adjacent adipose tissue and the tumor stroma (orange arrows), which produces LPA for signaling through cancer cell LPARs. This establishes a vicious cycle because LPA stimulates production of inflammatory cytokines and cyclooxygenase-2 (COX-2). Nuclear factor k light-chain enhancer of activated B cells (NF-kB) is activated in response DNA damage produced by radiotherapy, further increasing the concentrations of inflammatory mediators and ATX. Chemotherapy-induced oxidative damage can be mitigated by LPA signaling through PI3K, which increases nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) levels. This stimulates the production of antioxidant proteins and multidrug-resistance transporters (MDRTs) to attenuate oxidative damage and increase the efflux of chemotherapeutic drugs and toxic oxidation products from cancer cells.

750

Trends in Cancer, November 2017, Vol. 3, No. 11

Table 1. Drugs Targeting Autotaxin/LPA Signaling Currently in Clinical Trialsa

a

Drug

Target

Stage

Indication

Company

ClinicalTrials.gov ID

GLPG1690

Autotaxin inhibitor

Phase II

IPF

Galapagos NV

NCT02738801

BMS-986020

LPAR1 antagonist

Phase II

IPF

Bristol-Myers Squibb

NCT01766817

SAR100842

LPAR1/3 antagonist

Phase II

Systemic Sclerosis

Sanofi

NCT01651143

Lpathomab

LPA monoclonal antibody

Phase I



Lpath, Inc.

NCT02341508

In addition, multiple clinical trials are testing the use of tetracyclines for improving cancer treatments. This could involve an attenuation of LPA signaling by stabilizing LPP activity in addition to decreasing inflammation or matrix metalloproteinase activity. Abbreviation: IPF, idiopathic pulmonary fibrosis.

oxidative damage and against the accu- more inflammatory cytokines/chemomulation of cytotoxic drugs and toxic oxi- kines in thyroid tumors or in adipose tisdation products (Figure 1B) [14]. sue adjacent to breast tumors [4]. Inhibiting LPA signaling decreases the Radiation-induced cell damage and production of antioxidant enzymes and death also involves the production of the expression of multidrug-resistance reactive oxygen species, and this could transporters, which otherwise could proalso be attenuated by LPA-induced tect cancer cells from different chemostabilization of Nrf-2. We showed that therapies (Figure 1B) [14]. Inhibiting LPA irradiation of human breast adipose tis- signaling also provides a strategy for sue, such as would occur during multiple increasing the sensitivity of tumors to rounds of radiotherapy for breast cancer, radiotherapy [5,10]. stimulates an inflammatory response which involves increases in the expres- Finally, increasing the rate of LPA turnover sion of autotaxin, LPAR1, and LPAR2. by increasing the abnormally low expresThis response results from DNA damage sion of LPP1 and LPP3 in cancer cells and activation of NF-kB and COX-2 decreases tumor growth and metastasis (Figure 1B) [5]. This inflammation-medi- in mouse models of breast, thyroid, and ated increase in LPA signaling could ovarian cancer [8]. Tetracyclines stabilize diminish the efficacy of subsequent LPP protein expression at the cell surface, rounds of radiation treatment and contrib- thereby increasing overall LPA degradaute to radiation-induced fibrosis, espe- tion in a mouse breast cancer model [8]. cially through activation of LPAR1 [1]. This decreases NF-kB activation and inflammation in addition to the expected Targeting the Autotaxin–LPA–LPP inhibition of matrix metalloproteinase activities. The decreased LPA signaling Axis in Cancer Although targeting LPA signaling appears limits tumor macrophage infiltration and to be an attractive approach for cancer angiogenesis. Overall, these changes treatment, it is unlikely that this will be decrease breast tumor inflammation effective as a monotherapy. However, and tumor growth in preclinical models several modalities are in clinical trials to [8]. treat chronic inflammatory diseases and these demonstrate therapeutic efficacy Concluding Remarks (Table 1). The ability to block maladaptive The information that has been reviewed responses to chronic inflammation could has necessarily been restricted to publibe exploited as an adjuvant to improve cations appearing mainly in the past 3 existing cancer therapies. In support, years. The background to previous semiwork in mice shows that inhibiting auto- nal work can be obtained from these taxin activity reduces tumor growth partly citations. It is concluded from the recent by decreasing the concentrations of 16 or literature that maladaptive signaling

through the autotaxin–LPA–inflammatory axis is important in promoting tumor growth and metastasis. Chemotherapies and radiotherapy damage cells, thus eliciting an inflammatory response in addition to that created by the tumor. There is accumulating evidence that LPA-associated inflammation can contribute to cancer cell evasion of surveillance by the immune system. Consequently, various strategies for blocking signaling through the autotaxin–LPA–inflammatory axis (Table 1) could show promise as adjuvant treatments for improving the efficacy of existing chemotherapies, radiotherapy, and possibly immunotherapies. These treatments might also slow the progression of chronic inflammatory diseases to cancer. Blocking LPA signaling could also decrease some side effects of therapy such as radiation-induced fibrosis. The role of adipose tissue in producing autotaxin in response to inflammation produced by tumors is also emerging as an important promoter of breast cancer progression. In addition, autotaxin production by the omentum could facilitate basement membrane invasion and metastasis of multiple aggressive abdominal cancers including colon, ovarian, and pancreatic cancers. A significant advantage of targeting LPA signaling is that blocking pro-survival crosstalk between various cell populations in the tumor microenvironment impedes cancer cells from recovering from chemotherapy and radiotherapy damage. This could have potential for improving the efficacy of most current cancer therapies. Hence,

Trends in Cancer, November 2017, Vol. 3, No. 11

751

these treatments could be effective for a variety of tumors, and independently of specific mutations. Acknowledgments The work was supported by the Canadian Cancer Society Research Institute, the Canadian Breast Cancer Foundation, and the Women and Children’s Health Care Institute. D.N.B. has received consultancy payments and/or research funds from Ono Pharmaceuticals Ltd (Osaka, Japan) and Galapagos NV (Mechelen, Belgium). 1

Discipline of Surgery, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, A1B 3V6, Canada 2 Signal Transduction Research Group, Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada *Correspondence: [email protected] (D.N. Brindley). http://dx.doi.org/10.1016/j.trecan.2017.09.004

752

Trends in Cancer, November 2017, Vol. 3, No. 11

References 1. Rancoule, C. et al. (2017) Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index. Oncotarget 8, 43543–43554 2. Benesch, M.G.K. et al. (2015) Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J. Lipid Res. 56, 1134–1144 3. Ray, R. and Rai, V. (2017) Lysophosphatidic acid converts monocytes into macrophages in both mice and humans. Blood 129, 1177–1183 4. Benesch, M.G.K. et al. (2015) Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. FASEB J. 29, 3990–4000 5. Meng, G. et al. (2017) Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy. FASEB J. 31, 4064–4077 6. Federico, L. et al. (2016) Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J. Lipid Res. 57, 25–35 7. Llona-Minguez, S. et al. (2015) Lysophosphatidic acid receptor (LPAR) modulators: the current pharmacological toolbox. Prog. Lipid Res. 58, 51–75 8. Tang, X. et al. (2017) Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-kappaB activation. Mol. Cancer 16, 36

9. Mao, X.Y. et al. (2017) Genome-wide screen identifies a novel prognostic signature for breast cancer survival. Oncotarget 8, 14003–14016 10. Balogh, A. et al. (2015) The autotaxin–LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair. Cell Signal. 27, 1751–1762 11. Oda, S.K. et al. (2013) Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol. Res. 1, 245–255 12. Leblanc, R. et al. (2014) Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood 124, 3141–3150 13. Kanehira, M. et al. (2017) A lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells 35, 739–753 14. Venkatraman, G. et signaling stabilizes Nrf2 genes involved in drug responses: implications 29, 772–785

al. (2015) Lysophosphatidate and increases the expression of resistance and oxidative stress for cancer treatment. FASEB J.

15. Bekele, R.T. et al. (2016) Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci. Rep. 6, 21164